CF
IOVA icon

Cantor Fitzgerald’s Iovance Biotherapeutics IOVA Stock Holding History

Cantor Fitzgerald’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-254,879
Closed -$849K – 494
2025
Q1 		$849K Buy
+254,879
New +$1.31M 0.02% 123

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cantor Fitzgerald's IOVA Position: Q2 2025 in Review

Cantor Fitzgerald sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 254,879 shares — an estimated $849K sold.

Cantor Fitzgerald first reported a position in IOVA in Q1 2025 and held it in 1 quarter. The position peaked at $849K in Q1 2025. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Cantor Fitzgerald reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 254,879 Iovance Biotherapeutics shares in Q2 2025, an estimated $849K.
  • Cantor Fitzgerald first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • Cantor Fitzgerald's Iovance Biotherapeutics position peaked at $849K in Q1 2025.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Cantor Fitzgerald's 13F filing for Q2 2025, filed 14 Aug 2025.